Share

Related Links

Related Stories

  • Drug Discovery Oxford 2012
    The Drug Discovery Oxford 2012 – “Drug discovery: a job too complex for academia or industry alone?” conference is only a month away.
  • Proceedings of the 2nd Annual London Genetics Pharmacogenetics conference 2010 Pharmacogenetics: Why, How and When?
    The importance of pharmacogenetics and stratified medicine as part of the drug development processes is now widely acknowledge, offering the opportunity to address many of the challenges facing the biopharmaceutical industry today and supporting an era where cost-effectiveness and value-based pricing rule. Moving on from the inaugural London Genetics Pharmacogenetic conference in 2009, at which the role of pharmacogenetics in drug discovery and development was debated, the 2nd London Genetics conference, entitled ‘Pharmacogenetics – Why, How and When?’ focused on how and when to apply stratified approaches from drug discovery through to cost-effectiveness evaluation and reimbursement.
  • Research and development into tumour profiling will lead to improved cancer care
    Six new collaborative research and development projects are set to receive nearly £6 million of government funding in the latest stage of a major five-year initiative to ensure that the UK is a world leader in the development of personalised medicine.
  • Transatlantic research partnership aims for longer, healthier lives
    Research efforts to help the world's ageing population live longer, healthier lives have been given a major boost with the announcement of six new transatlantic research projects that aim to understanding the biology of the ageing process.
  • Cancer Research UK ploughs £21 million into new drug discovery programmes
    Cancer Research UK is set to extend its drug discovery effort by investing up to £16 million in two new Drug Discovery Programmes at the Paterson Institute for Cancer Research in Manchester and the Beatson Institute for Cancer Research in Glasgow.

Top 5 Stories

News

Oxford University launches new vaccinology programme

25 September 2009

Vaccine developers with insight into the latest advances will be drivers of innovation within the vaccine industry, yet there is a lack of available training courses in the field.

In response to this, the new Oxford Vaccinology Programme has been launched by the Jenner Institute, in collaboration with the University of Oxford Department for Continuing Education.

The courses will be taught by researchers from the University of Oxford and the Institute of Animal Health, complemented by guest speakers, including Dr David Salisbury (Director of Immunisation, UK Department of Health), Dr Alan Saul (Chairman, Novartis Vaccine Foundation), Dr Diane Williamson (UK Defence Science & Technology Laboratory), Dr James Merson (VP of Vaccines Research, Pfizer UK) and Professor Adrian Hill (Director of the Jenner Institute, University of Oxford).

The three short courses in the programme are aimed at research scientists, programme managers, clinical trial coordinators, physicians, veterinarians, those from industry and academia who already work in the field, and others who are seeking to enter it. The courses available are:

  • Human and Veterinary Vaccinology 9–13 November 2009 (five-day course)
  • Clinical Vaccine Development 16–17 November 2009 (two-day course)
  • Vaccine Biomanufacturing 18–19 November 2009 (two-day course)

The aim of the Oxford Vaccinology Programme is to provide a leading educational programme in vaccinology tailored to the needs of academia and industry alike by sharing the expertise of Jenner Investigators, both at the Institute for Animal Health and across the University of Oxford, complemented by the views and experience of distinguished outside speakers.

The Jenner Institute, which was founded in November 2005, was formed as a research partnership between the University of Oxford and the Institute of Animal Health. Vaccines developed by Jenner Institute Investigators against malaria, tuberculosis, HIV and influenza are currently in field trials in the UK and in the developing world. Research is also underway on livestock vaccines against foot-and-mouth disease, avian influenza, bovine tuberculosis and other key causes of economic loss. The CPD Centre offers a variety of workshops, seminars, short courses, certificates, diplomas and Master’s degrees, as well as online courses across a wide range of disciplines.

 

This article is featured in:
Companies and People

 

Comment on this article

You must be registered and logged in to leave a comment about this article.